Patents by Inventor Dana Leach
Dana Leach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7820633Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: May 19, 2003Date of Patent: October 26, 2010Assignee: BN Immunotherapeutics, Inc.Inventors: Lucilla Steinaa, Jesper Haaning, Iben Dalum, Peter Birk, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Anand Gautam, Søren Mouritsen
-
Patent number: 7807441Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: August 11, 2005Date of Patent: October 5, 2010Assignee: BN Immunotherapeutics, Inc.Inventors: Lucilla Steinaa, Søren Mouritsen, Anand Gautam, Iben Dalum, Jesper Haaning, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Peter Birk Rasmussen
-
Patent number: 7005498Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: October 5, 1999Date of Patent: February 28, 2006Assignee: Pharmexa A/sInventors: Lucilla Steinaa, Søren Mouritsen, Anand Gautam, Iben Dalum, Jesper Hanning, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Peter Birk Rasmussen
-
Publication number: 20060008465Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: ApplicationFiled: August 11, 2005Publication date: January 12, 2006Applicant: PHARMEXA A/SInventors: Lucilla Steinaa, Soren Mouritsen, Anand Gautam, Iben Dalum, Jesper Hanning, Dana Leach, Klaus Nielsen, Gunilla Karlsson, Peter Rasmussen
-
Publication number: 20050249700Abstract: T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.Type: ApplicationFiled: May 25, 2004Publication date: November 10, 2005Inventors: James Allison, Dana Leach, Matthew Krummel
-
Publication number: 20040141958Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: ApplicationFiled: May 19, 2003Publication date: July 22, 2004Applicant: M&E Biotech A/SInventors: Lucilla Steinaa, Soren Mouritsen, Anand Gautam, Jesper Haaning, Iben Dalum, Peter Birk, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson